8-K: Natera Reports Strong Preliminary Q4 and Full-Year 2025 Results

Natera announced preliminary unaudited financial results for Q4 and full-year 2025, showing significant revenue and test volume growth driven by record Signatera expansion.

Summary

• Preliminary unaudited total revenues for Q4 2025 are approximately $660 million, a 39% increase from $476 million in Q4 2024.
• Preliminary unaudited total revenues for full year 2025 are approximately $2.3 billion, a 35% increase from $1.7 billion in full year 2024.
• Full year 2025 revenues are approximately $40 million above the top end of Natera's financial outlook.
• Approximately 923,600 tests were processed in Q4 2025, a 17% increase from 792,800 tests in Q4 2024.
• Approximately 3,525,500 tests were processed in full year 2025, a 15% increase from 3,064,600 tests in full year 2024.
• Oncology tests, including clinical molecular residual disease (MRD) tests, increased by 55% in Q4 2025 compared to Q4 2024, with 233,300 oncology tests processed (225,300 clinical MRD tests).
• Clinical MRD tests saw a record sequential growth of approximately 22,800 tests in Q4 2025 over Q3 2025.
• Cash inflows for Q4 2025 were approximately $30 million, and greater than $100 million for full year 2025.

Sentiment

Score: 9

Explanation: The filing reports exceptionally strong preliminary financial results for Q4 and full-year 2025, significantly exceeding the company's own financial outlook. Record growth in key segments like oncology and clinical MRD tests, coupled with positive management commentary, indicates robust performance and strong future prospects, despite the preliminary nature of the data.

Positives

• Total revenues for full year 2025 are expected to increase by approximately 35% compared to 2024, reaching approximately $2.3 billion.
• Full year 2025 revenues are approximately $40 million above the top end of the company's financial outlook.
• Fourth quarter 2025 total revenues increased by approximately 39% to $660 million compared to $476 million in Q4 2024.
• Oncology tests, including clinical molecular residual disease (MRD) tests, showed significant growth, increasing by 55% in Q4 2025 compared to Q4 2024.
• Clinical MRD tests achieved a record sequential growth quarter in Q4 2025, increasing by approximately 22,800 tests over Q3 2025.
• 2025 was a record year for oncology, organ health, and women's health.
• Achieved cash inflows of greater than $100 million for the full year 2025.

Negatives

• Preliminary operational and financial results are unaudited and subject to revision, final adjustments, and audit, meaning actual results may differ materially.
• Cash inflows for Q4 2025 were approximately $30 million, a decrease from approximately $46 million in Q4 2024.

Risks

• Preliminary operational and financial results for Q4 and fiscal 2025 are subject to material changes and adjustments.
• Numerous uncertainties and challenges exist in achieving financial projections and goals.
• The company has incurred net losses since inception and anticipates continued net losses for the foreseeable future.
• Quarterly results may fluctuate from period to period.
• Estimates of market opportunity and forecasts of market growth may prove to be inaccurate.
• Additional risks and uncertainties are discussed in greater detail in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recent filings on Forms 10-K and 10-Q.

Future Outlook

The company believes it is well positioned to continue building on this momentum in 2026 and beyond, following a record year for oncology, organ health, and women's health.

Management Comments

• "2025 was a record year for oncology, organ health and womens health."
• "The fourth quarter was particularly strong, with excellent growth in volume, revenue and gross margins."
• "We believe we are well positioned to continue building on this momentum in 2026 and beyond."

Industry Context

Natera operates in the high-growth and innovative fields of cell-free DNA and precision medicine, focusing on oncology, women's health, and organ health. The strong performance, particularly in oncology with record Signatera growth, indicates the company is capitalizing on increasing demand for personalized genetic testing and diagnostics, aiming to establish these as standard-of-care.

Stakeholder Impact

• Shareholders: Likely positive impact due to strong revenue growth, exceeding financial outlook, and record performance in key segments, which could lead to increased share value.
• Employees: Positive impact from company growth, potentially leading to job security, expansion, and opportunities.
• Customers: Continued innovation and expansion in testing services (oncology, women's health, organ health) suggest improved access to advanced diagnostic tools.
• Creditors: Strong financial performance and cash inflows indicate improved ability to meet financial obligations.

Next Steps

• Present additional business updates and these results at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
• Release complete fourth quarter and full year 2025 financial results during an earnings call in February 2026.

Key Dates

Recommendation

Natera's preliminary Q4 and full-year 2025 results demonstrate exceptional growth, with full-year revenues exceeding the top end of their financial outlook by $40 million. The significant 35% year-over-year revenue increase and robust 55% growth in oncology tests, particularly record sequential growth in clinical MRD tests, highlight strong market penetration and demand for their precision medicine offerings. Despite the unaudited nature of these preliminary results, the magnitude of the outperformance and positive management outlook suggest a strong underlying business trajectory, making it a compelling 'strong buy' for investors seeking growth in the cell-free DNA and precision medicine space.

Keywords

Natera, NTRA, preliminary financial results, Q4 2025, full year 2025, revenue growth, test volume, oncology, Signatera, molecular residual disease, MRD, cell-free DNA, precision medicine, women's health, organ health, J.P. Morgan Healthcare Conference